Targeting a chemo-induced adaptive signaling circuit confers therapeutic vulnerabilities in pancreatic cancer
Yohei Saito,Yi Xiao,Jun Yao,Yunhai Li,Wendao Liu,Arseniy E. Yuzhalin,Yueh-Ming Shyu,Hongzhong Li,Xiangliang Yuan,Ping Li,Qingling Zhang,Ziyi Li,Yongkun Wei,Xuedong Yin,Jun Zhao,Seyed M. Kariminia,Yao-Chung Wu,Jinyang Wang,Jun Yang,Weiya Xia,Yutong Sun,Eek-hoon Jho,Paul J. Chiao,Rosa F. Hwang,Haoqiang Ying,Huamin Wang,Zhongming Zhao,Anirban Maitra,Mien-Chie Hung,Ronald A. DePinho,Dihua Yu
DOI: https://doi.org/10.1038/s41421-024-00720-w
IF: 38.079
2024-10-29
Cell Discovery
Abstract:Advanced pancreatic ductal adenocarcinomas (PDACs) respond poorly to all therapies, including the first-line treatment, chemotherapy, the latest immunotherapies, and KRAS-targeting therapies. Despite an enormous effort to improve therapeutic efficacy in late-stage PDAC patients, effective treatment modalities remain an unmet medical challenge. To change the status quo, we explored the key signaling networks underlying the universally poor response of PDAC to therapy. Here, we report a previously unknown chemo-induced symbiotic signaling circuit that adaptively confers chemoresistance in patients and mice with advanced PDAC. By integrating single-cell transcriptomic data from PDAC mouse models and clinical pathological information from PDAC patients, we identified Yap1 in cancer cells and Cox2 in stromal fibroblasts as two key nodes in this signaling circuit. Co-targeting Yap1 in cancer cells and Cox2 in stroma sensitized PDAC to Gemcitabine treatment and dramatically prolonged survival of mice bearing late-stage PDAC, whereas simultaneously inhibiting Yap1 and Cox2 only in cancer cells was ineffective. Mechanistically, chemotherapy triggers non-canonical Yap1 activation by nemo-like kinase in 14-3-3ζ-overexpressing PDAC cells and increases secretion of CXCL2/5, which bind to CXCR2 on fibroblasts to induce Cox2 and PGE2 expression, which reciprocally facilitate PDAC cell survival. Finally, analyses of PDAC patient data revealed that patients who received Statins, which inhibit Yap1 signaling, and Cox2 inhibitors (including Aspirin) while receiving Gemcitabine displayed markedly prolonged survival compared to others. The robust anti-tumor efficacy of Statins and Aspirin, which co-target the chemo-induced adaptive circuit in the tumor cells and stroma, signifies a unique therapeutic strategy for PDAC.
cell biology